Please use this identifier to cite or link to this item:
https://ahro.austin.org.au/austinjspui/handle/1/9684
Title: | Insulin-like growth factor binding protein-6 and CCI-779, an ester analogue of rapamycin, additively inhibit rhabdomyosarcoma growth. | Austin Authors: | Gallicchio, M A;van Sinderen, M;Bach, Leon A | Affiliation: | Department of Medicine, University of Melbourne, Austin Hospital, Studley Rd, Heidelberg, Victoria, 3084, Australia | Issue Date: | 12-Nov-2003 | Publication information: | Hormone and Metabolic Research = Hormon- Und Stoffwechselforschung = Hormones Et Me´tabolisme; 35(11-12): 822-7 | Abstract: | Rhabdomyosarcomas secrete high levels of insulin-like growth factor-II, suggesting this autocrine growth factor plays a major role in the unregulated growth of this childhood cancer. Treatment of Rh30 rhabdomyosarcoma cells with insulin-like growth factor binding protein-6 (IGFBP-6; 1000 ng/ml), which binds insulin-like growth factor-II with high affinity, inhibited growth in vitro (p < 0.001). Co-incubation of cells with rapamycin (1.56 ng/ml), an inhibitor of p70 S6 kinase, and IGFBP-6 (200 ng/ml) resulted in a significant reduction in Rh30 cell number compared to rapamycin or IGFBP-6 alone (p < 0.05 for both). Co-treatment of Rh30 cells with CCI-779 (5 and 50 ng/ml), an ester analogue of rapamycin, and IGFBP-6 (200 or 1000 ng/ml) also inhibited growth in vitro relative to CCI-779 alone (p < 0.01 and p < 0.001, respectively). In a nude mouse model, xenografts of Rh30 cells transfected with a recombinant vector encoding IGFBP-6 (phBP6-E3) showed delayed growth relative to vector control xenografts (27 days vs. 19 days to reach an average tumour volume of 0.5 cm (3); p < 0.001). Treatment with CCI-779 (10 mg/kg) of mice inoculated with vector control xenografts, also delayed growth (to 31 days; p = 0.0055) relative to untreated mice with vector control xenografts. Co-treatment with CCI-779 (10 mg/kg) reduced phBP6-E3 transfected xenograft growth even further (to 45 days) compared to vector control xenografts (p < 0.001, day 33). CCI-779 thus acts additively with IGFBP-6 to reduce rhabdomyosarcoma growth both in vitro and in vivo. | Gov't Doc #: | 14710364 | URI: | http://ahro.austin.org.au/austinjspui/handle/1/9684 | DOI: | 10.1055/s-2004-814153 | Journal: | Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et métabolisme | URL: | https://pubmed.ncbi.nlm.nih.gov/14710364 | Type: | Journal Article | Subjects: | Animals Cell Division.drug effects Cell Line Cell Line, Tumor Humans Insulin-Like Growth Factor Binding Protein 6.pharmacology Kidney Kinetics Mice Mice, Nude Recombinant Proteins.pharmacology Rhabdomyosarcoma.pathology Sirolimus.analogs & derivatives.pharmacology Transplantation, Heterologous |
Appears in Collections: | Journal articles |
Show full item record
Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.